SCHEMBL28030065

SCHEMBL28030065

Cc1ccccc1C(=O)OCCc1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 5/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ L3MBTL1 Q9Y468 3/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ TP53 P04637 2/20 0.52
▸ CYP3A4 P08684 2/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ GLA P06280 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ KDM4E B2RXH2 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ GAA P10253 1/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ CHRM5 P08912 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16673038 0.88 TSHR (0.67) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL17797782 0.84 TSHR (0.66) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL16049266 0.79 TSHR (0.59) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL17797867 0.79 TSHR (0.59) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL8433421 0.79 TSHR (0.59) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL17061429 0.78 ESR1 (0.64) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL14409194 0.78 TSHR (0.79) TSHRALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL812415 0.78 ALDH1A1 (0.55) TSHRALDH1A1NPC1L3MBTL1TDP1
SCHEMBL14984028 0.77 TSHR (0.68) TSHRALDH1A1L3MBTL1TDP1TP53
SCHEMBL29860709 0.77 TSHR (0.65) TSHRALDH1A1L3MBTL1TDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102947285-B Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases ABBVIE (US) 2015-08-26 — — CN disclosed
Send feedback